03.10.2017 • News

Asahi Develops CO2 Route to Diphenyl Carbonate

(c) Asahi Kasei
(c) Asahi Kasei

Japan’s Asahi Kasei has developed a new and safer route to produce diphenyl carbonate (DPC), using carbon dioxide (CO2) as a feedstock instead of phosgene, which is highly toxic. DPC is a feedstock used to make polycarbonate (PC).

In the two-step process, DPC is produced via dialkyl carbonate (DRC), using catalysts to produce DRC from CO2 and alcohol in a first stage and then producing DPC from DRC and phenol in a second stage.

The Tokyo-headquartered group has built a plant at its Mizushima works in Urashiki, Okayama, where it has validated the process’s stability and operability from more than 1,000 hours of continuous operation. It said that, compared to the traditional process, the new technology successfully reduced energy consumption and CO2 emissions.

Work will now continue to verify the process’s economy and energy efficiency, as well as to further optimize operating conditions and equipment as the company progresses to commercialization. Asahi Kasei said that validation of this process will strengthen and expand the group’s licensing business, which includes its non-phosgene PC technology that has been sold in countries such as China, South Korea, Taiwan, Russia and Saudi Arabia.

Asahi developed the DPC process as part of a project under Japan’s New Energy and Industrial Technology Development Organization (NEDO), which supports the development of energy-efficiency technologies.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

most read